Taiwan · Delayed Price · Currency is TWD Medigen Biotechnology Company Description
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan.
It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells.
It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States.
Medigen Biotechnology Corp. was founded in 1990 and is headquartered in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 1990 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Shun-Lang Chang |
Contact Details
Address: No.3, Park Street Taipei, 115603 Taiwan | |
| Phone | 886 2 7722 5200 |
| Website | medigen.com.tw |
Stock Details
| Ticker Symbol | 3176 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0003176004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Feng-Hua Chen | Finance Manager and Accounting Officer |
| Ya-Ling Chiang | Assistant Vice President of Operations and Management Department |
| Chin-Yen Chen | Assistant Vice President of Drug Development Department |
| Shun-Lang Chang | General Manager |